Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase NA 2Phase 2 2Phase EARLY_PHASE1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Genitourinary 2Gastrointestinal 2Breast 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Dermatologic 1CNS 1

Conditions

Prostatic Neoplasms 30Lung Neoplasms 30Carcinoma, Non-Small-Cell Lung 26Leukemia, Myeloid, Acute 25Multiple Myeloma 22Breast Neoplasms 20Lymphoma 18Carcinoma, Renal Cell 17Urinary Bladder Neoplasms 15Leukemia, Lymphocytic, Chronic, B-Cell 15Myelodysplastic Syndromes 14Lymphoma, Large B-Cell, Diffuse 14Colorectal Neoplasms 13Pancreatic Neoplasms 11Neoplasm Metastasis 11Ovarian Neoplasms 10Myeloproliferative Disorders 10Mouth Neoplasms 10Glioma 10Glioblastoma 10Burkitt Lymphoma 10Squamous Cell Carcinoma of Head and Neck 9Triple Negative Breast Neoplasms 8Sarcoma 8Rectal Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Melanoma 8Lymphoma, Non-Hodgkin 8Laryngeal Neoplasms 8Carcinoma 8

Interventions

Oxaliplatin 166Capecitabine 112Fluorouracil 95Docetaxel 85Cisplatin 84S 1 (combination) 83Leucovorin 64Paclitaxel 58Irinotecan 56pembrolizumab 36sintilimab 34Trastuzumab 34apatinib 30Bevacizumab 21Surgical Procedures, Operative 19Radiotherapy 19titanium silicide 17camrelizumab 17Nivolumab 17Ramucirumab 16Drug Therapy 15Hyperthermic Intraperitoneal Chemotherapy 14Folfox protocol 14Epirubicin 14tislelizumab 13Neoadjuvant Therapy 12Cetuximab 12XELOX 10Tegafur 10Carboplatin 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Stomach Neoplasms × Specimen Handling × Clear all
NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT04550494 2026-05-13

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

National Cancer Institute (NCI)

Phase 2 Recruiting
36 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡